Regulatory - Pharmaceutical Executive

ADVERTISEMENT

Regulatory
New developments and strategies for success in dealing with FDA, OIG, SEC, EMEA, and more.

Pharmacy Compounding: What's Ahead for Manufacturers

June 1, 2013

Compounders are under increased scrutiny following last year's spinal meningitis outbreak.

Unlocking the Key to Public Funding in Brazil

June 1, 2013

What is really driving decision making by the new Brazilian HTA agency? A look at appraisals issued in the first year.

Manufacturers Under Pressure to Manage Painkillers

May 6, 2013

Opioid abuse generates calls for efforts to curb distribution, develop abuse-resistant formulations.

European Biotech Struggles to Thrive

May 6, 2013

While not as bleak as believed, the outlook of European biotech sector is struggling compared with its US counterpart.

Obamacare Will Boost Private Managed Care

May 1, 2013

Public access expansion under the ACA isn't really a "government takeover."

Is That VBP on the Horizon, or a Mirage?

May 1, 2013

Value-based pricing in the United Kingdom is getting closer, but it remains out of focus.

Is National Drug Pricing Freedom in Europe Nearing its Expiry Date?

April 1, 2013

The European Union's attempt to update its transparency rules sparks new debate.

Who's Really in Charge of European Drug Registration?

March 1, 2013

European Commision blocks the authorization of a life-saving liver drug outside of France.

Another Round of FDA Legislation?

March 1, 2013

Pressure for action on key enforcement and regulatory issues may prompt congressional action this year.

ADVERTISEMENT

Click here